22 GHP Healthcare and Pharmaceutical Awards 2024 ounded 11 years ago by neuropharmacologists, Neuro-Sys boldly focuses exclusively on studies related to neurodegenerative diseases, placing a particular emphasis on Alzheimer’s, Parkinson’s, and Amyotrophic Lateral Sclerosis. “Our mission is to provide highly customized preclinical study solutions for our clients in the pharmaceutical and biotechnology industries,” explains Dr. Callizot. The company distinguishes itself through its ability to design and conduct custom studies that precisely meet the specific needs of each client. The in vitro and in vivo models developed by Neuro-Sys and used to validate compound-efficiency are not only well-validated, but also among the most advanced in the world. “A partner of excellence in neuropharmacology.” What truly sets Neuro-Sys apart from its competitors is its holistic approach. The company does not simply produce raw data for its clients, as is often the case in the industry. It goes far beyond, providing detailed pharmacological reports and high-level strategic advice. These in-depth analyses, performed by PhD level scientists, help clients to make informed and strategic decisions in their research and development programmes. Notably, many clients have adopted Neuro-Sys as their own research and development department. “Beyond the great satisfaction this brings us, it clearly demonstrates the trust that clients place in the Neuro-Sys team and the quality of our studies,” Dr. Callizot proudly states. This prominent level of trust and integration with clients’ research efforts emphasises the company’s commitment to excellence and its ability to deliver consistently high-quality results. The company’s excellence has been recently recognised with the prestigious title of Best Neurodegenerative Disease CRO 2024. “This award is a testament to the outstanding work and expertise of the Neuro-Sys team,” says Mr. Jaudouin. “It is a remarkable achievement that reflects our unwavering dedication to advancing research targeting neurodegenerative diseases.” Neuro-Sys’ global reach is certainly impressive, with over 90% of its activity conducted internationally, and more than 50% of that being Oct24213 F In the complex landscape of pharmaceutical research, one company stands out for its unique approach and deep expertise. Based in France, Neuro-Sys has established itself as an indispensable player in the field of neuropharmacology. Following the company’s recent recognition in the Healthcare and Pharmaceutical Awards 2024, we speak with Dr. Noelle Callizot, Neuro-Sys’ Co-Founder and CSO, and Mr. Jaudouin, CEO of Neuro-Sys, below. in the United States. This international presence underscores the company’s reputation and the high demand for its specialised services worldwide. To better serve its expanding client base Neuro-Sys has invested in a dedicated U.S.-based staff and is actively developing its presence in Asia. This expansion allows us to provide tailored support, enhanced responsiveness, and deep expertise in these key markets, driving growth initiatives and strengthening our global partnerships. The figures speak for themselves: Neuro-Sys conducts no less than 250 customised studies per year. Its team, 40% composed of PhD holders, operates in state-of-the-art facilities spanning over 22,000 square feet (2,000 sqm). These laboratories are equipped with the latest technologies, that generate accurate, repeatable data at the highest levels of efficiency. Neuro-Sys is more than just a service provider, however; the company is also deeply engaged in research and development. “We conduct numerous R&D studies to continuously improve and expand our in vitro and in vivo models,” emphasises Dr. Henriques, Director of Pharmacology at Neuro-Sys. This proactive approach has recently borne fruit, with the acquisition of a collaborative Eurostar project aimed at developing an innovative model for Frontotemporal Dementia. The company has recently reached a new growth milestone with its relocation to a larger facility. This strategic expansion significantly strengthens the Neuro-Sys’ ability to manage large-scale projects and collaborate with major players in the pharmaceutical industry. “Our new facilities not only allow us to increase our study volume, but also to expand our collaboration with the biggest names in the industry,” explains Mr. Jaudouin. Indeed, Neuro-Sys is now entering long-term contracts with some of the most prestigious biotech and pharmaceutical companies, supporting them in their research programmes. The solid growth of the company is also reflected in the planned expansion of its workforce, which is expected to reach 50 employees by the end of 2025. The future looks bright for Neuro-Sys; with its unique focus on neuropharmacology, recognised expertise, and state-of-the-art facilities, the company is well-positioned to become the leading Neurodegenerative Disease CRO in the market. In a sector where specialisation and expertise are crucial, Neuro-Sys stands out as an obvious choice for organisations seeking to advance the development of treatments for neurodegenerative diseases. “Our path forward is clear. We are on track to become the go-to partner for neurodegenerative disease research in the pharmaceutical industry,” Mr. Jaudouin confidently states. As the world faces an increase in neurodegenerative disease cases, the roles of companies like Neuro-Sys is becoming increasingly crucial. By combining scientific expertise, cuttingedge technologies, and a client-centric approach, Neuro-Sys is making a significant contribution to the advancement of research on these devastating diseases, offering renewed hope to the millions of people affected worldwide. Company: Neuro-Sys Web Address: https://www.neuro-sys.com/ Best Neurodegenerative Disease CRO 2024 – Europe
RkJQdWJsaXNoZXIy NTY1MjM3